参考文献
1. Tepper J, Krasna MJ, Niedzwiecki D,et al. Phase Ⅲ trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781[J]. J Clin Oncol, 2008, 26(7): 1086-1092.
2. Hagen PV, Hulshof MC, Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. N Engl J Med, 2012, 366(22): 2074-2084.
3. Ben M Eyck,J Jan B van Lanschot,Maarten C C M Hulshof,et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial[J]. J Clin Oncol . 2021,20;39(18):1995-2004.
4. Yang H, Liu H, Chen YP, et al. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial[J]. J Clin Oncol,2018;36(27):2796-2803.
5. Wang H, Tang H, Fang Y, et al. Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial[J]. JAMA Surg,2021;156(5):444-451.
6. Ken Kato, et al. A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExTstudyn[EB/OL]. ASCO-GI 2022 abs 238.
7. F Ge, Zy Huo, XY Cai, et al. Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis[J]. JAMA Netw Open . 2022;5(11):e2239778.
8. Hong MH , Kim HR , Park SY , et al . A phase Il trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma ( ESCC )[J]. J Clin Oncol ,2019,37(15_Suppl ):4027.
9. LI C, ZHAO S, ZHENG Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)[J]. Eur J Cancer, 2021, 144:232-241.
10. Jiang N, Jiang M, Zhu X, et al. SCALE-1: Safety and efficacy of short course neoadjuvant chemo-radiotherapy plus toripalimab for locally advanced resectable squamous cell carcinoma of esophagus[J]. 2022 ASCO Abs#4063.
11. Liu S, Wen J, Yang H, et al. Recurrence patterns after neoadjuvant chemoradiotherapy compared with surgery alone in oesophageal squamous cell carcinoma: results from the multicenter phase III trial NEOCRTEC5010[J]. Eur J Cancer. 2020;138:113-121.
12. Kelly RJ, Ajani JA, Kuzdzal J,et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer[J]. N Engl J Med 2021 ;384:1191-1203.